Durham, NCNCT07037836Now EnrollingIRB Ready

COPD (Chronic Obstructive Pulmonary Disease) Clinical Trial in Durham, NC

Access cutting-edge copd (chronic obstructive pulmonary disease) treatment through this clinical trial at a research site in Durham. Study-provided care at no cost to qualified participants.

Sponsored by Bastiaan Driehuys

Quick Self-Assessment

See if you qualify for this Durham location

Preparing your pre-screening questions…

Expert Care in Durham

Access copd (chronic obstructive pulmonary disease) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related copd (chronic obstructive pulmonary disease) treatment provided free

Apply for This Durham Location

Check if you qualify for this copd (chronic obstructive pulmonary disease) clinical trial in Durham, NC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Durham

    Convenient for NC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Durham site if eligible
  4. 4Begin participation

About This COPD (Chronic Obstructive Pulmonary Disease) Study in Durham

The goal of this clinical trial is to evaluate whether inhaled Treprostinil (Tyvaso) can improve oxygen delivery and blood flow in the lungs in adults (age ≥40) with chronic obstructive pulmonary disease (COPD) and hypoxemia who have less severe reduction in lung blood volume (diffusing capacity of the lungs for carbon monoxide \[DLCO\] ≥45%). The main questions it aims to answer are: 1. Does inhaled Treprostinil increase pulmonary capillary blood volume in ventilated lung regions, as measured by hyperpolarized xenon-129 magnetic resonance imaging (HP129Xe MRI)? 2. Does inhaled Treprostinil improve oxygen delivery (measured as red blood cell \[RBC\] chemical shift) and maintain or only slightly change pulmonary vascular resistance (measured by RBC oscillation amplitude)? 3. Can pre-treatment MRI parameters (RBC transfer and RBC oscillation amplitude) predict who will respond to inhaled Treprostinil? Participants will: * Use the Tyvaso nebulizer (inhaled Treprostinil) 4 times daily for 4 weeks, starting at 3 breaths per session and increasing to a maximum of 6 breaths per session as tolerated. * Undergo HP129Xe MRI before and after treatment to assess regional lung function and oxygen exchange. * Complete pulmonary function tests (PFTs), 6-minute walk tests (6MWT), and echocardiograms at the beginning and end of the study. * Be monitored for adverse events, with a phone check-in midway through and after the treatment period.

Sponsor: Bastiaan Driehuys

Who Can Participate

Inclusion Criteria

Outpatients of either gender, age ≥ 40.
Clinical evidence of chronic bronchitis (a productive cough lasting more than 3 months within a 2-year period).
Current or former cigarette smokers with a smoking history of 20 or more pack-years.
Clinical diagnosis of chronic obstructive pulmonary disease (COPD) confirmed by spirometry demonstrating forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio \< 0.70, pre-bronchodilator FEV1 ≥ 30% predicted, and diffusing capacity of the lungs for carbon monoxide (DLCO) ≥ 45% predicted.
On stable maintenance COPD medications including inhaled corticosteroids (ICS), long-acting beta agonists (LABA), long-acting muscarinic antagonists (LAMA), combination inhalers, azithromycin, or roflumilast (with no changes over the past 3 months).
Patients with hypoxemia, evidenced by the use of supplemental oxygen at rest or during exercise (≤ 4 liters/minute).
Willing and able to give informed consent and adhere to visit and protocol schedules (consent must be obtained prior to any study procedures).
Women of childbearing potential must have a negative serum pregnancy test, confirmed prior to participation in this investigational protocol.

Exclusion Criteria

Upper respiratory tract infection within 6 weeks (participants may be rescreened after this period).
History of lung resection surgery or pleural decortication.
Previous history of pneumothorax.
Imaging evidence of interstitial lung disease, occupational lung disease, or chronic infectious lung disease.
History of asthma.
History of exposure to occupational or environmental hazards known to cause lung disease.
Positive pregnancy test for women of childbearing potential.
Major chronic illness that, in the judgment of the study physician, would interfere with participation in the study. For Magnetic Resonance Imaging (MRI):
Contraindications to MRI based on screening questionnaire responses.
Participant is pregnant or lactating.
Respiratory illness of bacterial or viral etiology within 6 weeks prior to MRI.
Known cardiac arrhythmia.
Participant does not fit into the hyperpolarized xenon-129 (\^129Xe) vest coil used for MRI.
Participant cannot hold their breath for 10 seconds.
Participant is unlikely to comply with instructions during imaging.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Durham?

Yes, this clinical trial (NCT07037836) has an active research site in Durham, NC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

COPD (Chronic Obstructive Pulmonary Disease) Treatment Options in Durham, NC

If you're searching for copd (chronic obstructive pulmonary disease) treatment options in Durham, NC, this clinical trial (NCT07037836) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Durham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced copd (chronic obstructive pulmonary disease) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all copd (chronic obstructive pulmonary disease) clinical trials near you to find additional studies recruiting in your area.

More Parkinsons Disease Trials in Durham, NC

See all parkinsons disease clinical trials recruiting in Durham — not just this study.

Browse Parkinsons Disease Trials in Durham →

Browse More Trials by Condition

Parkinsons Disease TrialsUlcerative Colitis TrialsAnkylosing Spondylitis TrialsCOPD TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Durham?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Durham, NC